Briefing
TRACERx preoperative ctDNA was detected in 81% of lung adenocarcinomas with an ultrasensitive assay
A Nature Medicine paper published January 13, 2025, tested preoperative plasma from 171 TRACERx patients and detected ctDNA in 76 of 94 lung adenocarcinomas (81%), including 16 of 28 with stage I adenocarcinoma, and in 77 of 77 non-adenocarcinoma non-small cell lung cancers.